Chronic obstructive pulmonary disease (COPD)

Monoclonal antibodies
#Chronic obstructive pulmonary disease (COPD) #Connect Biopharma #Monoclonal antibodies #Phase II trial

Monoclonal antibody reduces COPD exacerbations in Phase II trial

Connect Biopharma has announced topline results from its global Phase II study evaluating rademikibart, a potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody.  The treatment was assessed as an add-on treatment for acute exacerbations in adult participants with chronic obstructive pulmonary disease (COPD) and type 2 inflammation. … Read More

#News

chronic obstructive pulmonary disease
#Cardiovascular disease #Chronic obstructive pulmonary disease (COPD) #Merck #Mergers and acquisitions

Merck acquires Verona, expands cardio-pulmonary portfolio

Merck (known as MSD outside of the US and Canada) is to acquire Verona Pharma for a total transaction value of approximately $10 billion.  Through this acquisition Merck will add Ohtuvayre (ensifentrine), a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), to its growing cardio-pulmonary pipeline… Read More

#Business & Investment #News

#Chronic obstructive pulmonary disease (COPD) #Monoclonal antibodies #Regeneron Pharmaceuticals #Sanofi

First biologic drug for COPD gets green light in US and China

Dupixent (dupilumab) has become the first biologic medicine for chronic obstructive pulmonary disease (COPD) in the US and China. Sanofi and Regeneron secured approvals from both the US Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA) in the same week. It is approved for adults with… Read More

#News #Regulatory

EMA concept
#Chronic obstructive pulmonary disease (COPD) #European Medicines Agency #Sanofi

Dupixent first targeted therapy for COPD approved in EU

The European Medicines Agency (EMA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils. The approval covers patients already on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA) and a long-acting muscarinic antagonist… Read More

#News #Regulatory #Trending News

Lungs
#Chronic obstructive pulmonary disease (COPD) #EpiEndo #Non-antibiotic macrolides #Phase II trial

Positive results announced for COPD therapy

Biopharmaceutical company EpiEndo has completed a Phase IIA clinical trial for its therapy addressing chronic obstructive pulmonary disease (COPD). EpiEndo is developing orally available, non-antibiotic macrolides, or Barriolides, that reduce inflammation while also limiting antimicrobial resistance (AMR). The company’s lead asset is EP395 and it focuses… Read More

#News

chronic obstructive pulmonary disease
#Approvals #Chronic obstructive pulmonary disease (COPD) #Drug approvals #FDA #Verona Pharma

Verona Pharma submits COPD drug ensifentrine for US FDA approval 

Verona Pharma has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for approval of ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).  Ensifentrine is a selective dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and non-steroidal… Read More

#News #Regulatory